跳至主要内容
临床试验/EUCTR2016-000411-32-NL
EUCTR2016-000411-32-NL进行中(未招募)1 期

AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Regeneron Pharmaceuticals, Inc.0 个研究点目标入组 8 人开始时间: 2016年5月17日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Men and women =18 years of age at the time of the screening visit
  • 2. Diagnosis of homozygous familial hypercholesterolemia (HoFH)
  • 3. Willing to consistently maintain usual diet for the duration of the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 8
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Background medical lipid modifying therapy that has not been stable for at least 4 weeks (6 weeks for fibrates) prior to the screening visit
  • 2. Having undergone lipid apheresis within 4 weeks prior to the screening visit
  • 3. Use of another investigational drug or therapy within 30 days or at least 5 half lives (whichever is longer) prior to the screening visit
  • 4. Previous participation in any clinical trial of REGN1500

研究者

相似试验

A study to the safety and efficacy of REGN1500 in... | 临床试验